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Abstract
 
Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1) is
known to function as a negative feedback regulator of cytokine signaling, but it is unclear
whether it is involved in other biological events. Here, we show that SSI-1 participates and
plays an important role in the insulin signal transduction pathway. SSI-1–deficient mice
showed a significantly low level of blood sugar. While the forced expression of SSI-1 reduced
the phosphorylation level of insulin receptor substrate 1 (IRS-1), SSI-1 deficiency resulted in
sustained phosphorylation of IRS-1 in response to insulin. Furthermore, SSI-1 achieves this in-
hibition both by binding directly to IRS-1 and by suppressing Janus kinases. These findings
suggest that SSI-1 acts as a negative feedback factor also in the insulin signal transduction path-
way through the suppression of IRS-1 phosphorylation.
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Introduction
 
Insulin is a central regulator of various metabolic processes
including cell growth, the uptake and metabolism of glu-
cose, the synthesis and storage of neutral fat, and protein
synthesis. Insulin mediates its biological effects through its
specific receptor, the insulin receptor (IR). Like many
growth factor receptors, IR has an intrinsic tyrosine kinase
activity and activation of this activity takes place upon insu-
lin binding (1, 2). Insulin receptor substrate (IRS) proteins
are substrate for IR and phosphorylated at multiple sites by
treatment not only with insulin but also with insulin-like
growth factor (IGF)-1 or IL–4 (1, 3). Phosphorylated IRS
functions as a docking protein for the Grb2 or p85 regula-
tory subunit of phosphatidylinositol 3-kinase (PI3K) and
endows the soluble factors, including insulin, with various
biological activities (1, 2). Both IRS-1– and IRS-2–defi-
cient mice showed insulin resistance (4–6), indicating that
IRS proteins are key molecules in insulin signaling. Inter-
estingly, it has been suggested that Janus kinases (JAKs) are
activated by insulin or IGF-1 treatment (7, 8).
Proteins of the signal transducer and activator of tran-
scription (STAT)-induced STAT inhibitor (SSI), also
known as suppressor of cytokine signaling (SOCS) or cy-
tokine-inducible src homology (SH)2 domain–containing
protein (CIS) family, have been identified as negative feed-
back regulators of the JAK-STAT signal transduction path-
way (9–11). So far, eight members of the SSI family gene
have been identified (12–14). All member proteins of this
family contain an SH2 domain in their central portion and
conserved SC motif, also known as a SOCS box, in their
COOH terminus (12–14). SSI-1 binds to the phosphoty-
rosine residue of JAK through its SH2 domain, and inhibits
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subsequent STAT activation by suppressing JAK activity
(12). Previously, SSI-1–deficient mice have been generated
and analyzed (15). SSI-1–deficient mice were normal at
birth, but showed severe growth retardation with aging.
They also showed atrophy in the thymus, a reduction in
the number of lymphocytes, and infiltration of mononu-
clear cells in several organs, and died within 3 wk after
birth (15).
In this report, we present evidence that SSI-1 is involved
in the insulin signal transduction pathway. Lower blood
sugar level was observed in SSI-1–deficient mice, indicat-
ing that deficiency of SSI-1 results in hypersensitivity to in-
sulin action. In addition, forced expression of SSI-1 re-
pressed the tyrosine phosphorylation of IRS-1, whereas
lack of SSI-1 prolonged IRS-1 phosphorylation after insu-
lin treatment. Furthermore, enhanced differentiation into
adipocytes was demonstrated in embryonic fibroblasts of
SSI-1–deficient mice in response to insulin. These results
suggest that SSI-1 plays an important role in the negative
regulation of the insulin signal transduction pathway
through suppression of IRS-1 phosphorylation. This SSI-1
is involved in a signaling pathway other than cytokine sig-
naling in vivo.
 
Materials and Methods
 
Blood Sugar, Serum Insulin, and Urine C-Peptide Level of SSI-1
 
2/2
 
Mice.
 
All observations were performed on 7–10-d-old SSI-1
 
1/1
 
and SSI-1
 
2/2
 
 mice. Blood was drawn from hearts, and blood
sugar level was determined. Serum insulin level was also mea-
sured by RIA. To measure the C peptide level, urine was col-
lected for 24 h, and the C peptide level was determined by
ELISA.
 
Glucose Uptake.
 
10
 
5
 
 cells were seeded on 6-well plates and
stimulated with insulin at the indicated concentration for 60 min.
2-deoxy-
 
D
 
-[1-
 
3
 
H] glucose (2DOG) and 0.1 mM unlabeled
2DOG were added, and incubation was continued for a further
20 min. After washing with ice-cold PBS twice, cells were solu-
bilized with 0.5 N NaOH and 0.1% SDS. Aliquots were assessed
for protein content and radioactivity.
 
Cell Culture.
 
L929 stably expressed SSI-1, SSI-3, or SOCS5,
and 293T cells were cultured in DMEM supplemented with 10%
FCS and 500 
 
m
 
g/ml of G418 (Nacalai Tesque). SSI-1–expressing
3T3-L1 cells were also maintained in G418 containing DMEM.
Murine embryonic fibroblast (MEF) cells were grown in DMEM
containing 10% FCS, nonessential amino acids (GIBCO BRL),
penicillin G, and streptomycin.
 
Insulin Stimulation In Vivo.
 
4-wk-old mice were fasted for
16 h, and then 5 U of human insulin were injected intraperito-
neally. At 10 min after injection, adipose tissue was dissected im-
mediately, lysed, and immunoprecipitatin was performed as de-
scribed below.
 
Induction of Adipocyte Differentiation.
 
Induction of adipocyte
differentiation was performed as described elsewhere (16). In
brief, MEFs collected from 13.5 days post coitum (dpc) embryos
were seeded onto 48-well plates, and propagated to confluence.
After 48 h, the culture medium was replaced by the induction
medium (DMEM containing 10% FCS, 0.5 mM 3-isobutyl-1-
methyl xanthine, 0.5 mM dexamethasone, and 5 
 
m
 
g/ml of insu-
lin). 2 d later, the induction medium was replaced with a mainte-
nance medium (DMEM supplemented with 10% FCS and 5 
 
m
 
g/
 
ml of insulin), which was renewed every other day. At day 6 of
differentiation, adipose drops in the cells were stained with Oil
Red-O and observed under a microscope. We used three inde-
pendent pairs of SSI-1
 
2/2
 
 and control mice from the same litter-
mate and obtained almost identical results.
 
Reverse Transcription PCR.
 
L929 cells were stimulated with
insulin and total RNA was isolated with the Total RNA Isolation
System (Promega). Reverse transcription (RT) reaction was per-
formed by using oligo dT primer and Moloney murine leukemia
virus reverse transcriptase (Stratagene). The PCR reaction con-
sisted of the following steps: 95
 
8
 
C for 1 min, 65
 
8
 
C for 1 min,
72
 
8
 
C for 1 min, 37 cycles for SSI-1; 95
 
8
 
C for 1 min, 62
 
8
 
C for 1
min, 72
 
8
 
C for 1 min, 38 cycles for SSI-3 and 32 cycles for
SOCS5; and 95
 
8
 
C for 1 min, 60
 
8
 
C for 1 min, 72
 
8
 
C for 1 min,
and 21 cycles for glyceraldehyde 3-phosphate dehydrogenase
(G3PDH). The primer pairs were: SSI-1, 5
 
9
 
-CACCTTC-
TTGGTGCGCGACA-3
 
9
 
 and 5
 
9
 
-GCAGCTCGAAAAG-
GCAGTCG-3
 
9
 
; SSI-3, 5
 
9
 
-CCATGGTCACCCACAGCAAG-
3
 
9
 
 and 5
 
9
 
-GTAAGCCCTCAAGGACCTAG-3
 
9
 
; SOCS5,
5
 
9
 
-CAGACAGGGAGCTTGGAAAG-3
 
9
 
 and 5
 
9
 
-GTTGAAGT-
CGAAGCTACGGG-3
 
9
 
; G3PDH, 5
 
9
 
-ACCACAGTCCATG-
CCATGCCATCAC-3
 
9
 
 and 5
 
9
 
-TCCACCACCCTGTTGCT-
GTA-3
 
9
 
.
 
Antibodies.
 
Anti–SSI-1 monoclonal antibody, 1262B (17),
anti–SSI-3, and anti-SOCS5 polyclonal antibodies (Santa Cruz
Biotechnology, Inc.) were used. Anti-JAK1 and anti-Tyk2 mono-
clonal antibodies were purchased from Transduction Laboratory,
anti-IR, anti-JAK2, and anti–IRS-1 polyclonal antibodies from
Santa Cruz Biotechnology, Inc., and antiphosphotyrosine mono-
clonal antibody, 4G10, from Upstate Biotechnology. Horseradish
peroxidase (HRP)-conjugated anti–rabbit and anti–mouse IgG
(Amersham Pharmacia Biotech) and HRP-conjugated anti–goat
IgG (Southern Biotechnology Associates, Inc.) were used as sec-
ond antibodies for Western blot analysis.
 
Immunoprecipitation and Western Blot Analysis.
 
Serum-starved
L929 cells were treated with 10 nM insulin or 10 nM IGF-1 for
the times indicated. The cells were lysed with an NP-40 lysis
buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP-40,
10 mM Na
 
2
 
VO
 
4
 
, 0.5 mM dithiothreitol, 1 
 
m
 
g/ml pepstatin A, 1
 
m
 
g/ml leupeptin, and 1 mM PMSF) and clarified by centrifuga-
tion. The supernatants were collected and incubated with the an-
tibodies indicated for 16 h at 4
 
8
 
C. After incubation with protein
A–sepharose 4B (Amersham Pharmacia Biotech) for 1 h, the
beads were washed with the NP-40 lysis buffer four times, and
then immunecomplex was resolved by 8% SDS-PAGE. The pro-
teins were transferred onto a nitrocellulose filter (Schleicher &
Schuell). After blocking with 5% skim milk, the filter was incu-
bated with one of the first antibodies, and then with the appro-
priate second antibody. After washing, the signals were visualized
by the ECL system (Amersham Pharmacia Biotech).
 
Transient Transfection.
 
293T cells were transfected with 2 
 
m
 
g
of pEF-BOS-SSI-1, 2 
 
m
 
g of pEF-BOS-SSI-3, 2 
 
m
 
g of pEF-
BOS-SOCS5, 5 
 
m
 
g of pEF-BOS-JAKs, 5 
 
m
 
g of pGEM3 SV
HIR-IR, 3 
 
m
 
g of pCIBSD-IRS-1, or a combination of these ex-
pression plasmids with the standard calcium coprecipitation
method. After 36 h, cells were harvested and subjected to West-
ern blot analysis as described above with the indicated antibodies.
 
Results
 
Deficiency of SSI-1 Resulted in Hypoglycemia.
 
To charac-
terize the physiological role of SSI-1 in vivo, we have pre-
viously generated mice which lack the SSI-1 gene (SSI-1
 
2/2 
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mice; reference 15). SSI-1
 
2/2
 
 mice showed marked apop-
tosis in their lymphocytes and died within 3 wk after birth.
Through the biochemical analyses of SSI-1
 
2/2
 
 mice, we
noticed that the blood sugar level of SSI-1
 
 2/2
 
 mice was
significantly lower than that of SSI-1
 
1/1
 
 mice (Fig. 1 A;
 
1/1
 
: 136.2 
 
6
 
 26.5 mg/dl,
 
 n 
 
5 
 
7; 
 
2/2
 
: 84.9 
 
6
 
 13.3 mg/
dl,
 
 n 
 
5 
 
7). However, the urine C peptide level of SSI-1
 
2/2
 
mice was no higher than that of SSI-1
 
1/1
 
 mice (Fig. 1 B;
396 
 
6 
 
99.57 vs. 401.2 
 
6 
 
97.19 ng/day,
 
 n 
 
5 
 
6). Consistent
with this, the serum insulin level of SSI-1
 
2/2
 
 
 
mice was also
no higher than that of SSI-1
 
1/1
 
 mice (Fig. 1 C; 
 
1/1
 
: 0.71 
 
6
 
0.40 ng/ml,
 
 n 
 
5 
 
5; 
 
2/2
 
: 0.56 
 
6 
 
0.38 ng/ml,
 
 n 
 
5 
 
5).
These results indicated that the reduction in blood sugar
level of SSI-1
 
2/2
 
 mice was not due to the insulin level itself
but to a change in sensitivity to insulin action. We specu-
lated that SSI-1 also might act as a negative regulator of in-
sulin signal transduction as well as of cytokine signaling and
that SSI-1
 
2/2
 
 mice might become hypersensitive to insulin
action because of the lack of a suppression mechanism.
To confirm this idea, we established SSI-1–expressing
3T3 L1 cells (L1/SSI-1) and performed a 2DOG uptake
experiment (Fig. 1 D). L1/neo cells were facilitated on up-
taking 2DOG in response to insulin, but in three indepen-
dent clonal cell lines, L1/SSI-1/1, L1/SSI-1/2, and L1/
SSI-1/3, 2DOG uptake was decreased compared with the
parental cell line. It is noteworthy that the basal level of
2DOG uptake was also decreased in L1/SSI-1 cells, maybe
due to the unresponsiveness to serum containing insulin in
L1/SSI-1 cells. These results suggest that the expression
level of SSI-1 affects the insulin action.
 
SSI-1 Inhibits the Phosphorylation of IRS-1 in Response to
Insulin.
 
To elucidate how SSI-1 suppresses the insulin
signal transduction, we first examined the effect of the SSI-1
protein on insulin signaling. SSI-1 is thought to bind the
phosphotyrosine residue and block the phosphorylation
cascade. Therefore, we expected that the forced expression
of SSI-1 would alter the protein phosphorylation pattern
after insulin treatment. We established the cell line L929/
SSI-1 which stably expressed SSI-1 in L929 mouse fibro-
blast cells (20). Examination of the tyrosine phosphoryla-
tion pattern of total cellular proteins after insulin stimula-
tion showed that phosphorylation of an 
 
z
 
180-kD protein
was significantly reduced in the L929/SSI-1 cells compared
with L929/neo which was transfected with an empty vec-
tor (Fig. 2 A, indicated by arrow). Insulin stimulation in-
duces the tyrosine phosphorylation of IRS-1 with a molec-
Figure 1. SSI-12/2 mice show low
blood sugar level. (A) Blood sugar level,
(B) urine c-peptide level, and (C) serum
insulin level were measured in 7–10-
d-old mice. r, raw data. Mean values 6
SE are indicated as filled circles and ver-
tical bars. (D) 3T3-L1/neo and three in-
dependent clones of 3T3-L1/SSI-1 cells
were stimulated with insulin at 0 (white
bar), 1 (hatched bar), and 10 nM (black
bar) for 60 min, and incubated with
2DOG for a further 20 min. Each value
is the mean 6 SE of triplicate determi-
nations. 
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ular mass of 
 
z
 
180 kD (1, 2). Therefore, we examined
whether the reduced phosphorylation protein in L929/
SSI-1 cells was the same as IRS-1. We also included SSI-3
and SOCS5 in this experiment because it has been reported
that SSI-3 is induced by leptin or prolactin treatment and
suggested that SSI-3 might be involved in metabolic regu-
lation (18, 19); Emanuelli et al. (21) showed that SSI-3 was
induced by insulin, bound to IR, and inhibited STAT5 ac-
tivation, and SOCS5 is induced after insulin stimulation as
described below. To do this, we also established the cell
lines L929/SSI-3 and L929/SOCS5, which expressed SSI-3
and SOCS5, respectively. Insulin treatment induced
strong phosphorylation of IRS-1 in L929/neo cells (Fig. 2
B, top, lanes 1–4), whereas it was significantly reduced in
L929/SSI-1 cells (Fig 2. B, top, lanes 5–8). L929/SSI-3
cells also showed suppression of IRS-1 phosphorylation,
Figure 2. SSI family proteins
modulate the phosphorylation
state of IRS-1. (A) L929/neo
(lanes 1–4) and L929/SSI-1
(lanes 5–8) cells were stimulated
with insulin for 0 (lanes 1 and 5),
10 (lanes 2 and 6), 30 (lanes 3
and 7), and 60 min (lanes 4 and
8). Total cell lysates were sub-
jected to Western blot analysis
with antiphosphotyrosine anti-
body. Arrow indicates reduced
phosphorylation band in L929/
SSI-1 cells. (B) L929/neo (lanes
1–4), L929/SSI-1 (lanes 5–8),
L929/SSI-3 (lanes 9–12), or
L929/SOCS5 (lanes 13–16) cells
were treated with insulin (top
and second panels) or IGF-1
(third and bottom panels) for the
indicated times. Tyrosine phos-
phorylation of IRS-1 was ana-
lyzed (top and third panels) by
immunoprecipitation followed
by Western blot analysis. The second and bottom panels show that equal amounts of IRS-1 were immunoprecipitated. (C) MEFs derived from SSI-11/1
(lanes 1–4) and SSI-12/2 (lanes 5–8) were treated with insulin and the phosphorylation state of IRS-1 was detected as in B. IP, immunoprecipitation;
WB, Western blot analysis; pY, phosphotyrosine.
Figure 3. Inhibition mecha-
nism of IRS-1 phosphorylation
by SSI-1 and SSI-3. (A) 293T
cells were transfected with the
expression vector carrying IR
(lane 1), SSI-1 or SSI-3 (lane 2),
or a combination of IR and SSI-1
or SSI-3 (lane 3), treated with
insulin for 10 min before har-
vesting (lane 4), and then immu-
noprecipitated with an anti-IR
antibody. Association of SSI-1
and SSI-3 with IR (top panel)
and the kinase activity of IR
(second panel) were analyzed by
Western blot analysis using anti-
SSI antibody and antiphosphoty-
rosine antibody, respectively. (B)
293T cells were transfected with
the expression vector as indi-
cated. After 36 h, cells were
lysed and immunoprecipitated
with an anti–IRS-1 antibody.
Then Western blot analysis was
performed with anti-SSI antibody (top). (C) IR-transfected 293T cells (left) were untreated (lane 1) or treated with insulin for 10 min (lane 2) and immu-
noprecipitated with anti–IRS-1 antibody. The immunecomplex was subjected to Western blot analysis with anti-JAK1 (top), anti-JAK2 (second panel),
and anti–IRS-1 antibody (bottom). 4-wk-old mice were also stimulated with 5 U of insulin for 10 min. Fat cells were removed and processed as above
(right). (D) 293T cells were transfected with IRS-1 (lanes 1, 6, and 11) or cotransfected IRS-1 with JAKs (JAK1, lanes 1–5; JAK2, lane 6–10; Tyk2, lanes
11–15), with JAKs and SSI-1 (lanes 3, 8, and 13), with JAKs and SSI-3 (lanes 4, 9, and 14), or with JAKs and SOCS5 (lanes 5, 10, and 15) expression
vectors. Cells were lysed, immunoprecipitated with anti–IRS-1 antibody, and then subjected to Western blot analysis phosphotyrosine antibody to ex-
amine the phosphorylation state of IRS-1 (top panel). *IgG light chain.267 Kawazoe et al. Brief Definitive Report
but their inhibitory effect was rather weak compared with
L929/SSI-1 cells (Fig 2. B, top, lanes 9–12). In contrast to
L929/SSI-1 and L929/SSI-3 cells, strong phosphorylation
of IRS-1, almost the same as seen in L929/neo cells, was
observed in L929/SOCS5 cells (Fig. 2 B, top, lanes 13–16).
IRS-1 is also phosphorylated by treatment with IGF-1 (2).
Therefore, we analyzed the effect of SSI family proteins on
IGF-1–stimulated IRS-1 phosphorylation and obtained al-
most the same result as with insulin (Fig. 2 B, bottom).
Then, we analyzed whether SSI-1 deficiency led to aug-
mentation of IRS-1 phosphorylation as a result of insulin
treatment. Strong induction of IRS-1 phosphorylation was
detected after 10 min of insulin stimulation, and it gradually
declined at 60 and 180 min after stimulation in SSI-11/1
MEFs (Fig. 2 C, top, lanes 1–4). In contrast, intense phos-
phorylation of IRS-1 in SSI-12/2 MEFs lasted, at least, up
to 180 min (Fig. 2 C, top, lanes 5–8). These results suggest
that SSI-1 and SSI-3 are capable of suppressing insulin sig-
naling at the level of IRS-1 phosphorylation.
SSI-1 Suppresses the Phosphorylation of IRS-1 by Directly
Binding. We next studied the precise molecular mecha-
nism by which SSI-1 and SSI-3 inhibit IRS-1 phosphory-
lation induced by insulin. Since SSI-1 is known to bind
and inhibit JAKs (11, 17), we considered that SSI-1 might
act on IR in the same way. To this end, IR, SSI-1, or SSI-3
was transiently expressed in 293T cells, and the associa-
tion of IR with SSI-1 or SSI-3 and the kinase activity of
IR after insulin stimulation were analyzed. We found that
neither SSI-1 nor SSI-3 either bound to IR or inhibited IR
kinase activity (Fig. 3 A), which was consistent with our
previously published data showing that SSI-1 could not
suppress IR kinase activity in SSI-1–expressing M1 cells
(9). Subsequently, we examined whether SSI-1/3 inhibited
the phosphorylation of IRS-1 by binding to IRS-1 di-
rectly. 293T cells were transfected with IRS-1, SSI-1, or
SSI-3 expression vector and cell extracts were prepared.
After immunoprecipitation with anti–IRS-1 antibody, as-
sociation of SSI-1/3 with IRS-1 was detected by Western
blot analysis with anti–SSI-1/3 antibody. Binding of SSI-1
to IRS-1 was barely observed before insulin stimulation
(Fig. 3 B, left, lane 3). However, when cells were stimu-
lated with insulin, a substantial level of SSI-1 was coprecip-
itated with IRS-1 (Fig. 3 B, left, lane 4). This result indi-
cated that SSI-1 preferentially bound to phosphorylated
IRS-1, which suppressed further phosphorylation. On the
other hand, we could not detect the association between
SSI-3 and IRS-1 even after insulin stimulation in 293T
cells (Fig. 3 B, right).
SSI-1 Inhibits IRS-1 Phosphorylation Also by Inhibiting
JAKs. In spite of the lack of association of SSI-3 with
IRS-1, SSI-3 still inhibits the IRS-1 phosphorylation (Fig.
2 B). Therefore, we further studied the inhibition mecha-
nism of IRS-1 phosphorylation. Based on the fact that IL-
4, IL-9, IL-13, and oncostatin M, whose receptors do not
contain an intrinsic kinase activity, evoke the phosphoryla-
tion of IRS-1, and on the recent reports which demon-
strated that JAKs are phosphorylated by insulin treatment
(7, 8), we examined the involvement of JAKs in insulin sig-
naling. First, we demonstrated the association of JAKs with
IRS-1. The interaction between IRS-1 and JAK1 or JAK2
(Fig. 3 C, lanes 1 and 2) but not Tyk2 (data not shown)
was detected only after insulin treatment. Furthermore, we
Figure 4. SSI-12/2 MEFs show enhanced induction of differentiation into adipocytes by insulin. (A and C) MEFs derived from SSI-11/1 mice or (B
and D) SSI-12/2 mice were induced to differentiate into adipocytes as described in Materials and Methods. Three independent littermate pairs were used
for experiments, and representative results are shown. The lipid drops in the cells were stained red by Oil Red-O. Original magnification: 320. (E) L929
cells were treated with insulin and total RNA was isolated. RT-PCR analysis was then performed as described in Materials and Methods.268 Inhibition of Insulin Signaling by SSI-1
also found that JAK1 bound to IRS-1 in the adipose tissue
in vivo after insulin stimulation (Fig. 3 C, lanes 3 and 4).
Unfortunately, we could not detect the association of JAK2
and IRS-1 in the adipose tissue, maybe because of the low
expression level of JAK2 in adipose tissue. These results in-
dicated that JAKs are capable of binding to IRS-1 with in-
sulin stimulation–dependent manner. Moreover, JAK1 and
JAK2, but not Tyk2, bound to IR in 293T cells (data not
shown).
We next investigated whether IRS-1–bound JAKs could
phosphorylate IRS-1 and whether SSI family proteins
could inhibit this process. It is known that the forced ex-
pression of JAKs results in their autophosphorylation and
activation. Therefore, IRS-1 and JAKs together with SSI-1,
SSI-3, or SOCS5, were coexpressed in 293T cells. Coex-
pression with JAK1 resulted in a significant level of IRS-1
phosphorylation. However, the degree of IRS-1 phos-
phorylation was greatly reduced by the coexpression of
SSI-1 or SSI-3 with JAK1. Coexpression of SOCS5 with
JAK1, on the other hand, did not affect JAK1 activity on
IRS-1 phosphorylation (Fig. 3 D, top, lanes 1–5), which is
consistent with the inhibition specificity of IRS-1 phos-
phorylation in L929 cell lines (Fig. 2 B). Furthermore, we
obtained almost the same results for JAK2 as for JAK1 (Fig.
3 D, top, lanes 6–10). In contrast, the effect of Tyk2 on
IRS1 phosphorylation was very weak compared with JAK1
and JAK2 (Fig. 3 D, top, lanes 11–15), which is parallel to
the binding specificity of IRS-1 to JAKs and suggested that
JAK1 and JAK2 might be involved in insulin signaling.
SSI-1 2/2 MEFs Show Enhanced Differentiation into Adipo-
cytes by Insulin. For further confirmation of involvement
of SSI-1 in insulin signaling, we used an established adipo-
cyte differentiation system in which MEFs convert into
mature adipocyte in the presence of adipogenic hormones
such as insulin (16). We expected that if SSI-1 acts as a
negative regulator in the insulin signaling, SSI-1 deficiency
should lead to the enhancement of differentiation. As ex-
pected, MEFs derived from SSI-12/2 mice showed burst
induction of differentiation into adipocytes compared with
SSI-11/1 MEFs after 6 d of insulin treatment (Fig. 4, A and
B). An additional 6 d of induction with insulin resulted in
almost the same proportion of MEFs derived from SSI-11/1
mice as those derived from SSI-12/2 mice differentiating
into adipocytes (Fig. 4, C and D). These results clearly in-
dicate that SSI-1 can function as a negative regulator of in-
sulin signaling.
Induction of SSI Family mRNAs in Response to Insulin.
Finally, we examined the induction of the SSI family
mRNAs after insulin stimulation to determine whether SSI
families function as a feedback regulator for insulin. The
result indicated that SSI-1, SSI-3, and SOCS-5 mRNAs
were all induced after insulin stimulation (Fig. 4 E).
Discussion
SSI-1 has been thought to function as an inhibitor of the
cytokine signal transduction pathway. This report demon-
strates that SSI-1 is also involved in the insulin signal trans-
duction pathway in vivo. SSI-1 suppresses the insulin signal
transduction pathway at the level of the phosphorylation of
IRS-1 by interaction with IRS-1 and inhibiting JAKs acti-
vated by insulin and does not affect IR kinase activity. On
the other hand, SSI-3 suppresses IRS-1 phosphorylation
only by inhibiting JAKs. These differential inhibition
mechanisms of IRS-1 phosphorylation between SSI-1 and
SSI-3 are consistent with Fig. 2 B, demonstrating that the
inhibitory effect of SSI-1 was stronger than that of SSI-3.
Although it is shown that SSI-3 directly bound to IR and
inhibited STAT5 activation in response to insulin (20), it is
evident that SSI-1 may play an important role in vivo be-
cause SSI-12/2 mice show low blood sugar level even in
the presence of SSI-3. In addition, we could not observe
direct binding of SSI-1 and SSI-3 to IR in 293T cells but
demonstrated that they suppressed IRS-1 phosphorylation.
Our study showed that SSI-1 might be capable of inhib-
iting all effector molecules activated by JAKs. Since the
identification of SSI-1, it has been thought to act as a nega-
tive regulator specific for STAT activation by inhibiting
the activity of JAKs in vivo. However, our results suggest
that SSI-1 may have the potential to suppress effector mol-
ecules other than STATs. For example, IL-4 stimulation
induces not only STAT6 activation but also phosphoryla-
tion of IRS proteins. Therefore, SSI-1 might inhibit both
of these transduction pathways in IL-4 signaling. In addi-
tion, we demonstrated that SSI-1 associated with IRS-1
and suppressed further phosphorylation of IRS-1. Al-
though it has been shown that SSI-1 could interact with
various signaling molecules including c-kit, vav, and Grb-2
(22), the biological significance of this interaction is not yet
clear. Therefore, our findings established a novel concept
of SSI-1 function.
In recent years, several reports suggested that TNF-a or
INF-g antagonizes insulin action and generates an insulin-
resistant state (23, 24). These phenomena raise a clinical
point that patients with cytokine treatment frequently suf-
fer from diabetes. Our present study suggests a possibility
that SSI-1 might be involved in cytokine-induced diabetes
because both TNF-a and INF-g induce SSI-1 (21). Fur-
thermore, our unpublished data indicate that SSI-1 is indis-
pensable to the cross-talk inhibition between several cyto-
kines, for example, INF-g stimulation does not antagonize
IL-4 signaling in SSI-1–deficient T cells (Naka, T., H.
Tsutsui, Y. Kawazoe, H. Kohzaki, Y. Morita, R. Naka-
gawa, M. Narazaki, K. Adachi, T. Yoshimoto, K. Naka-
nishi, and T. Kishimoto, unpublished observation). There-
fore, our study suggests that SSI-1 might regulate the
cross-talk not only of cytokine signaling but also between
cytokine and endocrine hormones, and SSI-1 may be ap-
plicable to insulin-resistant diabetes.
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